Phil Ambery

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

Phil Ambery, Victoria E R Parker, Michael Stümvoll et al. · The Lancet · 2018 · 295 citations

Obesity, Metabolic Syndrome, Medicine +7

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

Rajaa Nahra, Tao Wang, Kishore M. Gadde et al. · Diabetes Care · 2021 · 295 citations · Full text

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

Mikhail Kosiborod, Russell Esterline, Remo H.M. Furtado et al. · The Lancet Diabetes & Endocrinology · 2021 · 235 citations · Full text

Cardiovascular Disease, Cardiometabolic Risk, Cardiovascular Pharmacology +11

Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist

Victoria E R Parker, Darren Robertson, Tao Wang et al. · The Journal of Clinical Endocrinology & Metabolism · 2019 · 115 citations · Full text

Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes

Natalie M. Edner, Frank Heuts, Niclas Thomas et al. · Nature Immunology · 2020 · 90 citations · Full text

Type 1, Diabetes Management, Autoimmune Disease +12